By Counterforce Health Team in Entresto (sacubitril/valsartan) —

Myths vs. Facts: Getting Entresto (sacubitril/valsartan) Covered by Humana in Illinois

Quick Answer: Humana Medicare Advantage plans in Illinois require prior authorization for Entresto with documented heart failure (LVEF ≤40%), ACE inhibitor/ARB trial and failure/intolerance, and 36-hour ACE inhibitor washout. If denied, you have 65 days to appeal, plus Illinois external review rights within 4 months. Start by checking your specific plan's formulary and gathering complete ACE/ARB trial documentation.

Table of Contents

Why Myths Persist About Entresto Coverage

Getting Entresto (sacubitril/valsartan) covered by Humana in Illinois can feel like navigating a maze of conflicting information. Patients and even some clinicians operate on assumptions that don't match how prior authorization actually works. These myths persist because insurance policies change annually, requirements vary between plan types, and the appeals process involves both federal Medicare rules and Illinois state protections.

The stakes are high: Entresto costs hundreds of dollars monthly without coverage, and delays can worsen heart failure outcomes. Understanding what's myth versus fact can mean the difference between quick approval and months of denials.

Counterforce Health helps patients and clinicians cut through this confusion by turning insurance denials into targeted, evidence-backed appeals. The platform identifies the real denial basis and drafts point-by-point rebuttals aligned to each plan's specific rules.

Common Myths vs. Facts

Myth 1: "If my cardiologist prescribes Entresto, Humana has to cover it"

Fact: Prescription alone doesn't guarantee coverage. Humana requires prior authorization for Entresto, typically as a Tier 3 non-preferred drug. You need documented chronic systolic heart failure (ICD-10 I50.22) with LVEF ≤40-50% from recent imaging, plus evidence of ACE inhibitor or ARB trial and failure/intolerance.

Myth 2: "I can't get Entresto covered because I never tried an ACE inhibitor"

Fact: You can still get approval if ACE inhibitors are contraindicated. Document prior angioedema, severe hyperkalemia, or other contraindications with specific dates and lab values. Humana's step therapy requirements allow exceptions for documented contraindications or intolerance.

Myth 3: "Appeals take forever and rarely work"

Fact: Illinois has some of the fastest appeal timelines in the country. Internal appeals must be decided within 15 business days for pre-service requests (24 hours if expedited). External review through the Illinois Department of Insurance takes about 5 business days once assigned to an Independent Review Organization.

Myth 4: "Generic Entresto is available, so Humana won't cover brand"

Fact: While generic approvals exist, market availability is limited due to ongoing litigation. Most plans still treat sacubitril/valsartan as brand-only for coverage purposes. Check your specific Humana formulary for current status.

Myth 5: "I need to see a cardiologist first to get approval"

Fact: While cardiology involvement strengthens your case, Humana's published criteria don't explicitly require a cardiologist as prescriber. However, having cardiology consultation documented can help overcome "medical necessity" denials.

Myth 6: "If Entresto isn't on my formulary, I can't get it covered"

Fact: Humana offers formulary exceptions for non-formulary drugs when medically necessary. Your prescriber must submit a supporting statement explaining why all formulary alternatives are inadequate, likely to be ineffective, or would cause adverse effects.

Myth 7: "I have to wait weeks between stopping my ACE inhibitor and starting Entresto"

Fact: The required washout period is only 36 hours, not weeks. This safety requirement prevents dangerous interactions between ACE inhibitors and Entresto's neprilysin inhibitor component.

Myth 8: "Once denied, I can't resubmit for months"

Fact: You can resubmit immediately with additional documentation. Many denials result from incomplete information rather than true medical necessity issues. Adding detailed ACE/ARB trial history, recent echo results, or specialist notes often leads to approval on resubmission.

What Actually Influences Approval

Documentation That Matters Most

Heart Failure Evidence:

  • Explicit chronic systolic heart failure diagnosis (avoid unspecified codes like I50.9)
  • Numeric LVEF value with date (echo, MUGA, or cardiac MRI within 6-12 months)
  • NYHA functional class with specific symptoms
  • Recent hospitalizations or emergency visits for heart failure

ACE Inhibitor/ARB History:

  • Specific drug names, doses, and durations
  • Clear reasons for discontinuation (side effects, ineffectiveness, contraindications)
  • Dates when medications were started and stopped
  • Lab values supporting adverse effects (creatinine, potassium, blood pressure)

Clinical Context:

  • Current guideline-directed heart failure medications
  • Ejection fraction trends over time
  • Quality of life impact and functional limitations
  • Treatment goals and monitoring plan

Submission Strategy

Counterforce Health's analysis of successful Entresto appeals shows that approvals often hinge on how the request is framed. Instead of simply stating "patient needs Entresto," effective submissions explain why continuing current therapy would be inadequate and how Entresto addresses specific clinical gaps.

Use Humana's preferred submission methods:

  • CoverMyMeds portal (fastest processing)
  • Provider portal for real-time status updates
  • Fax to 888-447-3430 for urgent cases
  • Phone line 866-461-7273 (M-F 8am-11pm ET) for complex cases

Avoid These Preventable Mistakes

1. Submitting Without Complete ACE/ARB Documentation

The Problem: Most Entresto denials cite "no evidence of ACE/ARB trial" or "step therapy not met."

The Fix: Document every ACE inhibitor or ARB tried, including:

  • Drug name and class (e.g., "lisinopril, ACE inhibitor")
  • Starting dose and target dose achieved
  • Duration of therapy (specific dates when possible)
  • Reason for discontinuation with objective data
  • Example: "Lisinopril titrated from 5mg to 20mg daily over 6 weeks, used for 4 months, discontinued due to persistent cough interfering with sleep"

2. Missing the 36-Hour Washout Documentation

The Problem: Concurrent ACE inhibitor use is an absolute contraindication for Entresto.

The Fix: Explicitly state that ACE inhibitor has been discontinued and document the 36-hour washout plan. Update medication lists to show ACE inhibitor removal before Entresto start date.

3. Using Vague Heart Failure Descriptions

The Problem: Generic terms like "heart failure" without specifics trigger automatic denials.

The Fix: Use precise language:

  • "Chronic heart failure with reduced ejection fraction (HFrEF)"
  • "NYHA Class III symptoms with LVEF 25% on echo dated [specific date]"
  • Include ICD-10 code I50.22 (chronic systolic heart failure)

4. Ignoring Plan-Specific Requirements

The Problem: Assuming all Humana plans have identical criteria.

The Fix: Check your specific plan's prescription drug guide for current year requirements. Medicare Advantage, Part D standalone, and employer group plans may have different criteria.

5. Missing Appeal Deadlines

The Problem: Illinois has strict timelines - 65 days for internal appeals, 4 months for external review.

The Fix: Mark deadlines immediately upon receiving denial letters. File appeals well before deadlines to allow for processing delays or requests for additional information.

Quick Action Plan: 3 Steps to Take Today

Step 1: Verify Your Coverage Status

  • Log into your Humana member portal and search for "Entresto" or "sacubitril/valsartan"
  • Note the formulary tier, any restrictions (PA, step therapy, quantity limits)
  • Download your plan's current prescription drug guide
  • If non-formulary, prepare for a formulary exception request

Step 2: Gather Required Documentation

From Your Medical Records:

  • Most recent echocardiogram or cardiac imaging with numeric LVEF
  • Cardiology consultation notes (if available)
  • Complete medication history with ACE inhibitors/ARBs tried
  • Heart failure hospitalization records
  • Current lab results (creatinine, potassium, BNP/NT-proBNP)

From Your Prescriber:

  • Request a detailed medical necessity letter addressing:
    • Specific heart failure diagnosis and severity
    • Prior ACE/ARB trials with outcomes
    • Clinical rationale for Entresto
    • Monitoring and follow-up plan

Step 3: Submit Strategically

  • Use CoverMyMeds or Humana provider portal for fastest processing
  • Include all supporting documentation with initial submission
  • Request expedited review if you have recent hospitalizations or worsening symptoms
  • Track submission status and respond quickly to any requests for additional information
From our advocates: We've seen cases where patients were initially denied Entresto coverage, but approval came quickly once the medical necessity letter included specific ACE inhibitor trial details and recent hospitalization records. The key is often in the details - not just that treatments failed, but exactly how they failed and when. This is a composite example based on common successful appeal patterns, not a guarantee of specific outcomes.

Resources and Next Steps

Illinois-Specific Appeal Rights

  • Illinois Department of Insurance External Review: File within 4 months of final denial
  • Consumer Assistance Hotline: 877-527-9431
  • Illinois Attorney General Health Care Helpline: 1-877-305-5145

Humana Resources

Financial Assistance Options

  • Novartis Patient Assistance: Entresto.com financial support
  • Medicare Extra Help: For Part D cost-sharing assistance
  • Illinois Medicaid: If eligible as Medicare-Medicaid dual eligible

When to Escalate

Contact the Illinois Department of Insurance if:

  • Humana doesn't respond within required timeframes
  • You believe proper procedures weren't followed
  • You need help understanding your appeal rights
  • The denial appears to contradict published policy

Coverage advocacy platforms like Counterforce Health can help translate complex denial letters into targeted appeals, pulling the right evidence and citations to build stronger cases for medications like Entresto.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances, specific plan terms, and current policies. Always consult with your healthcare provider about treatment decisions and contact your insurance plan or the Illinois Department of Insurance for official guidance on coverage and appeals.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.